140 related articles for article (PubMed ID: 18791058)
1. Disappearance of bone marrow B cell clonal expansion in patients with type II hepatitis C virus-related cryoglobulinemic glomerulonephritis after clinical efficient rituximab therapy.
Quartuccio L; Salvin S; Fabris M; Sacco S; De Vita S
Ann Rheum Dis; 2008 Oct; 67(10):1494-5. PubMed ID: 18791058
[No Abstract] [Full Text] [Related]
2. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.
Roccatello D; Baldovino S; Rossi D; Mansouri M; Naretto C; Gennaro M; Cavallo R; Alpa M; Costanzo P; Giachino O; Mazzucco G; Sena LM
Nephrol Dial Transplant; 2004 Dec; 19(12):3054-61. PubMed ID: 15494358
[TBL] [Abstract][Full Text] [Related]
3. [Monoclonal antibodies to B-lymphocytes (rituximab) in the treatment of HCV-associated severe cryoglobulinemic glomerulonephritis].
Milovanova SIu; Lopatkina TN; Kozlovskaia LV; Krasnova TN
Ter Arkh; 2007; 79(6):69-72. PubMed ID: 17684972
[No Abstract] [Full Text] [Related]
4. HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies.
Garini G; Allegri L; Lannuzzella F; Vaglio A; Buzio C
Acta Biomed; 2007; 78(1):51-9. PubMed ID: 17687818
[TBL] [Abstract][Full Text] [Related]
5. Therapy of hepatitis C virus-associated glomerulonephritis: current approaches.
Fabrizi F; Lunghi G; Messa P; Martin P
J Nephrol; 2008; 21(6):813-25. PubMed ID: 19034865
[TBL] [Abstract][Full Text] [Related]
6. Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft.
Bestard O; Cruzado JM; Ercilla G; Gomà M; Torras J; Serón D; Rama I; Ibernon M; Viñas O; Carrera M; Grinyó JM
Nephrol Dial Transplant; 2006 Aug; 21(8):2320-4. PubMed ID: 16751656
[No Abstract] [Full Text] [Related]
7. The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders.
Landau DA; Rosenzwajg M; Saadoun D; Klatzmann D; Cacoub P
Ann Rheum Dis; 2009 Mar; 68(3):337-44. PubMed ID: 18434450
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow B-cell clonal expansion in type II mixed cryoglobulinaemia: association with nephritis.
Quartuccio L; Fabris M; Salvin S; Isola M; Soldano F; Falleti E; Beltrami CA; De Re V; De Vita S
Rheumatology (Oxford); 2007 Nov; 46(11):1657-61. PubMed ID: 17893101
[TBL] [Abstract][Full Text] [Related]
9. Acute wrist and foot drop associated with hepatitis C virus related mixed cryoglobulinemia: rapid response to treatment with rituximab.
Uppal R; Charles E; Lake-Bakaar G
J Clin Virol; 2010 Jan; 47(1):69-71. PubMed ID: 19892591
[TBL] [Abstract][Full Text] [Related]
10. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients.
Basse G; Ribes D; Kamar N; Mehrenberger M; Sallusto F; Esposito L; Guitard J; Lavayssière L; Oksman F; Durand D; Rostaing L
Transplant Proc; 2006 Sep; 38(7):2308-10. PubMed ID: 16980074
[TBL] [Abstract][Full Text] [Related]
11. [Membranoproliferative glomerulonephritis in patients with cryoglobulinemia complicating hepatitis C virus: report of 11 cases].
Ben Fatma L; Ben Hamida F; Aoudia R; Goucha R; Kaaroud H; Béji S; Barbouch S; Hedri H; Abderrahim E; Elyounsi F; Ben Abdallah T; Ben Moussa F; Kheder A
Tunis Med; 2007 Mar; 85(3):220-4. PubMed ID: 17668578
[TBL] [Abstract][Full Text] [Related]
12. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab.
Cai FZ; Ahern M; Smith M
J Rheumatol; 2006 Jun; 33(6):1197-8. PubMed ID: 16755669
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia.
Korte MR; van Heerde MJ; de Man RA; Betjes MH
Neth J Med; 2008 Jan; 66(1):27-30. PubMed ID: 18219065
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of HCV-associated cryoglobulinemic glomerulonephritis].
Laurino S; Borrelli S; Catapano F; Mascia S; D'Angio' P; Calabria M; Grimaldi M; Salvio A; Minutolo R; De Nicola L; Conte G
G Ital Nefrol; 2009; 26(3):318-27. PubMed ID: 19554529
[TBL] [Abstract][Full Text] [Related]
15. Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases.
Lu TY; Jónsdóttir T; van Vollenhoven RF; Isenberg DA
Ann Rheum Dis; 2008 Oct; 67(10):1493-4. PubMed ID: 18791057
[No Abstract] [Full Text] [Related]
16. Cryoglobulinemic glomerulonephritis: clinical presentation and histological features, diagnostic pitfalls and controversies in the management. State of the art and the experience on a large monocentric cohort treated with B cell depletion therapy.
Rossi D; Sciascia S; Fenoglio R; Ferro M; Baldovino S; Kamgaing J; Ventrella F; Kalikatzaros I; Viziello L; Solfietti L; Barreca A; Roccatello D
Minerva Med; 2021 Apr; 112(2):162-174. PubMed ID: 33198442
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for the treatment of type II mixed cryoglobulinemia.
Zaja F; De Vita S; Russo D; Michelutti A; Fanin R; Ferraccioli G; Baccarani M
Arthritis Rheum; 2002 Aug; 46(8):2252-4; author reply 2254-5. PubMed ID: 12209536
[No Abstract] [Full Text] [Related]
18. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate.
Owczarczyk K; Hellmann M; Fliedner G; Röhrs T; Maizus K; Passon D; Hallek M; Rubbert A
Ann Rheum Dis; 2008 Nov; 67(11):1648-9. PubMed ID: 18854518
[No Abstract] [Full Text] [Related]
19. Hepatitis C virus infection, type III cryoglobulinemia, and necrotizing vasculitis.
Brownell I; Fangman W
Dermatol Online J; 2007 Jan; 13(1):6. PubMed ID: 17511939
[TBL] [Abstract][Full Text] [Related]
20. Clonal expansion of B-cells in human systemic lupus erythematosus: evidence from studies before and after therapeutic B-cell depletion.
Sfikakis PP; Karali V; Lilakos K; Georgiou G; Panayiotidis P
Clin Immunol; 2009 Jul; 132(1):19-31. PubMed ID: 19345151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
